ABSTRACT: Mutationally activated Ras is one of the most common oncogenic drivers found across all malignancies, and its selective inhibition has long been a goal in both pharma and academia. One of the oldest and most validated methods to inhibit overactive Ras signaling is by interfering with its post-translational processing and subsequent cellular localization. Previous attempts to target Ras processing led to the development of farnesyltransferase inhibitors, which can inhibit H-Ras localization but not K-Ras due to its ability to bypass farnesyltransterase inhibition through alternative prenylation by geranylgeranyltransferase. Here, we present the creation of a neosubstrate for farnesyltransferase that prevents the alternative prenlation by geranylgeranyltransferase and mislocalizes oncogenic K-Ras in cells.
T he ability to associate with membranes is a critical feature for the cellular localization and activity of many proteins. 1, 2 Early studies of the Ras oncogene highlighted these features when deletions localized to the C-terminal tail were found to prevent its membrane localization, which in turn prevented the ability of oncogenic Ras mutants from transforming cells. 3 Further work identified the cysteine residue four amino acids from the C-terminus that is conserved in all Ras proteins as necessary for their membrane localization. 4 This cysteine along with the three terminal amino acids define the CaaX motif, which was found to be sufficient to signal for the covalent attachment of either a geranylgeranyl lipid group by geranylgeranyltransferase (GGTase) or, in the case of Ras, a farnesyl group catalyzed by farnesyltransferase (FTase) to the targeted cysteine. 2, 5, 6 This alkylation is then followed by the cleavage of the three terminal amino acids and methylation of the new C-terminal carboxyl group to create a hydrophobic C-terminus suitable for interacting with membranes ( Figure 1 , path a). 7, 8 The finding that this post-translational modification was necessary for Ras signaling drove the development of numerous potent peptidomimetic farnesyltransferase inhibitors (FTI) in order to target the roughly 16% of cancers containing activating Ras mutations. 9 These agents showed exceptional activity in HRas driven preclinical models with robust inhibition of Ras's transforming ability and no obvious dose limiting toxicities. 10, 11 However, in clinical trials dominated by patients harboring the more common K-Ras mutations, the inhibitors failed to show any significant benefit over the control arms. 12, 13 This unanticipated failure was largely attributed to several previously unappreciated differences in the processing of the various Ras isoforms. K-Ras4b, the predominant isoform of KRas in cells (hereafter referred to as K-Ras), was found to bind to FTase more strongly than H-Ras, which would necessitate a higher drug concentration to effectively block K-Ras farnesylation.
14 Additionally, while H-Ras is solely a substrate of FTase, in the presence of an FTI, K-Ras can be alternatively prenylated by GGTase, providing a cellular bypass mechanism that allows for its proper downstream processing, membrane localization, and signaling (Figure 1 path b) . 14, 15 Several attempts were made to develop either selective GGTase inhibitors that could be used in combination with an FTI or dual inhibitors of FTase and GGTase. Among these were high doses of statins, which prevent the cellular biosynthesis of precursors to farnesyl pyrophosphate and geranylgeranylpyrophosphate, thereby allowing them to act as dual inhibitors. This attempt along with other dual inhibitor strategies have encountered potential toxicity issues associated with GGTase inhibition that have limited their clinical advancement. 1, 16 The failure of farnesyl transferase inhibitors to cause mislocalization of K-Ras led us to wonder if an alternative chemical strategy based on farnesyl transferase could be employed. We envisioned developing an alternative substrate for farnesyl transferase, which could covalently modify the K-Ras C-terminal cysteine. Such a strategy would prevent subsequent processing steps while simultaneously blocking alternative prenylation, resulting in the mislocalization of K-Ras to the cytoplasm. Here, we describe the design of such neo-substrates for FTase and demonstrate their ability to covalently modify the CaaX motif of K-Ras in an FTase-dependent manner in vitro. Cell permeable pro-drugs were shown to mislocalize multiple different oncogenic mutants of K-Ras into the cytoplasm and when combined with statins inhibit oncogenic K-Ras signaling. These results suggest this neo-substrate strategy for blocking KRas prenylation may prove to be a viable approach toward inhibiting a broad spectrum of Ras oncogenes.
■ RESULTS
Design and Activity of Electrophilic Farnesyl Transferase Inhibitors of K-Ras. In designing a pharmacological strategy for K-Ras inhibition, we sought a solution that would circumvent both the issue of K-Ras's high affinity for FTase and its ability to bypass inhibition through GGTase. We hypothesized that if we could irreversibly label the normally farnesylated cysteine of K-Ras with a small molecule it would prevent all forms of prenylation and prevent the subsequent processing and translocation steps, thereby compromising the ability of K-Ras to signal ( Figure 1, path c) . Since the C-terminal tail of K-Ras is relatively unstructured with no obvious nearby pockets for a small molecule inhibitor to derive binding affinity, we envisioned harnessing the active site of FTase to deliver the inhibitor to KRas.
As a starting point for the design of a neo-substrate for FTase, we analyzed the crystal structure of the farnesyl-competitive FTI 1 bound to FTase and the C-terminal peptide of K-Ras (Figure 17 FTI 1 features a hydroxamate ester and a phosphonate, which together mimic the pyrophosphate moiety of farnesyl pyrophosphate. The most useful observation from the structure was that the hydroxamate nitrogen is only about 6 Å from the target K-Ras cysteine and is oriented in such a way that attaching an electrophile at this position would likely direct it toward the cysteine. However, direct incorporation of an amide-linked electrophile at this nitrogen would result in an unstable Nalkoxyimide structure; thus we made some simplifying adjustments to improve the chemical stability and facilitate the synthesis of multiple analogs, arriving at the general structure 2 ( Figure 2b ).
The vinylsulfonamide 3 was the first FTase neo-substrate synthesized to show covalent labeling of recombinant full-length K-Ras in an FTase-dependent reaction, as judged by intact protein liquid chromatography−mass spectrometry (LC/MS). While only labeling 6% of the total K-Ras, it was encouraging that no reaction was observed in the absence of FTase, indicating that the enzyme is in fact promoting the non-natural reaction. The low intrinsic reactivity of 3 in the absence of FTase could potentially be attributed to the unfavorable repulsive interaction between the negatively charged phosphonate and an approaching negatively charged nucleophile. Such interactions would be alleviated by the positively charged active site residues of FTase effectively neutralizing the negatively charged phosphonate.
Switching the electrophile from the vinyl sulfonamide to a propynamide (4) did not by itself improve the extent of K-Ras labeling. However, the combination of the propynamide and adding one methylene spacer between the electrophile and phosphonate improved the conjugation to 45% (5) . While the activity of 5 was encouraging, we were concerned about the nonspecific toxicity of the reactive propynamide electrophile. 18 We considered that we might fare better with an electrophilic warhead whose reactivity could be enhanced by the active site of FTase. In this regard, epoxides stood out as a group susceptible to Lewis and Brønsted-acid catalysis that could potentially take advantage of the positively charged residues and zinc cofactor present in the active site. In fact, epoxy amide 6 proved to be just such an electrophile with lower uncatalyzed reactivity than 5 and improved FTase-dependent K-Ras labeling (54%) as determined by this method. A representative LC/MS chromatogram of KRas following the reaction with 6 in the presence of FTase is shown in Figure 2c . Importantly, we were unable to detect covalent labeling of K-Ras in the analogous experiment without FTase using this method. We also explored dicarboxylates as an alternative phosphomimetic group (compound 7); however, this resulted in compounds with reduced activity compared to 6. Finally, we prepared as a negative control a desoxy analog of 6 that lacks the epoxide electrophile. As expected, we were unable to detect any labeling of K-Ras with the resulting compound (8) using this assay.
One outstanding question was whether neo-substrate 6 could undergo transfer to other protein substrates of FTase in addition to K-Ras. From a therapeutic standpoint, it would presumably be desirable if the neo-substrate showed at least some specificity for K-Ras over other farnesylated proteins. To investigate this, we treated a purified sample of the closely related protein H-Ras under identical conditions using compound 6 and FTase. However, no covalent labeling was detected in this assay (SI, Figure S1 ), whereas the positive control farnesylation reaction using farnesyl pyrophosphate proceeded as expected. We considered two explanations for the apparent selectivity. First, K-Ras is known to be among the tightest binding and overall most efficient substrates of FTase. 19 It is reasonable to think that this higher efficiency might also carry over to our unnatural neosubstrate. Additionally, previous work examining FTasecatalyzed prenylation reactions of various peptides has shown that certain prenyl donors can show selectivity for one peptide sequence, while others can have inverted selectivity. 20−25 Thus, it is possible that our use of K-Ras labeling as a primary screen led us to a neo-substrate that is in fact partially optimized for K-Ras over other farnesylated proteins, although it is unlikely that this degree of specificity would apply to all of the prenylated substrates within a cell.
Naturally, we had some concern surrounding the fact that our neo-substrates retain a farnesyl-like tail and thus could conceivably still target K-Ras for proper membrane localization. However, we noted that the K-Ras-6 adduct has an exposed negatively charged phosphonate as well as an α-hydroxy amide resulting from epoxide opening. Upon deeper consideration, it seemed unlikely to us that the K-Ras-6 adduct would be similar enough to farnesylated K-Ras to undergo the remaining steps of post-translational processing (enzymatic proteolysis and methylation) as well as carrier-promoted trafficking to the membrane. We also note that the K-Ras-inhibitor complex could itself act as an inhibitor of FTase, which could explain our inability to achieve greater than 54% labeling of K-Ras.
Neosubstrate 6 Mislocalizes mCerulean K-Ras (G12C).
In order to evaluate the cellular activity of the phosphonate containing compounds, we masked the phosphonate moiety of compound 6 and the negative control 8 as a dipivalate ester prodrug (referred to as 6* and 8*). We then evaluated the ability of the cell permeable 6* and 8* to mislocalize a dox-inducible mCerulean K-Ras containing the oncogenic mutation G12C (mCerulean K-Ras (G12C)). A 9 h induction of mCerulean KRas showed that the labeled K-Ras was properly processed and trafficked to the periplasmic membrane (Figure 3a) . Treatment of cells with high doses of the HMG Co-A reductase inhibitor lovastatin, which prevents the cellular synthesis of both the farnesyl-pyrophosphate and geranylgeranyl pyrophosphate substrates thus acting as a dual FTase and GGTase inhibitor, prevented this accumulation at the membrane, as did 6*. In contrast, the nonelectrophilic inhibitor 8* had no effect on the localization of K-Ras (Figure 3a) .
In order to quantify the degree of K-Ras mislocalization, we measured the fluorescence intensity of the labeled K-Ras across a linescan spanning from a cell's cytoplasm toward the extracellular space. We then applied a sigmoidal fit to the fluorescent signal that was used to align all scans at the sigmoidal midpoint, i.e., the membrane's edge. A representative example for cells treated either with DMSO or 6* is shown in Figure 3b with the linescan shown as an arrow and the resulting trace highlighted in red. Linescans were generated from 50 cells per condition, each shown in gray. The ratio of membrane localized K-Ras to cytoplasmic K-Ras was calculated (representative example in SI Figure S2 ) and demonstrated that 6* but not the nonelectrophilic 8* is capable of mislocalizing oncogenic K-Ras into the cytoplasm as effectively as the positive control compound lovastatin. 
Compound 6 Prevents K-Ras Bypass of FTase
Inhibitors and Mislocalizes K-Ras. We next evaluated the ability of our inhibitors in the PSN-1 cell line, which contains a G12R K-Ras mutation and has previously been shown to bypass FTase inhibition. 26 Cellular fractionation validated that K-Ras could escape both a peptide competitive, L744,832 (L744), or a farnesyl pyrophosphate competitive, FPT inhibitor III (FPT3), FTI and maintain its proper membrane localization (Figure 4a ). However, targeting both FTase and GGTase using either lovastatin (Lova) or the GGTase inhibitor, GGTI 298 (GG), in addition to the peptide competitive FTase inhibitor (L744+GG) resulted in robust mislocalization of K-Ras to the cytoplasm (Figure 4a ). Similar to the dual inhibitor treatment and consistent with the fluorescently tagged Ras system, 6* but not 8* was able to successfully alter the localization of K-Ras to the cytoplasm (Figure 4a ). This activity was both time and dose dependent (Figure 4b, c) and was also seen in SW-620 cells, which have a G12 V K-Ras mutation (SI, Figure S3 ). To verify that the cellular activity of neo-substrate 6* was dependent on FTase as it was in vitro and not an artifact of the electrophile, we treated cells with either 6* alone or in combination with increasing doses of the peptide competitive FTase inhibitor. We hypothesized that the peptide competitive FTase inhibitor would prevent K-Ras from coming into contact with the 6 + FTase complex and allow it to bypass the neo-substrate through GGTase. As shown in Figure 4d , this cotreatment strategy was effective in preventing the mislocalization of K-Ras into the cytoplasm, indicating that the cellular ability of 6* to mislocalize K-Ras is dependent on FTase.
To evaluate the effect of mislocalizing K-Ras from the membrane on MAPK signaling, we probed p-ERK levels in PSN-1 cells after a 24 h of treatment with a dose response of 6*. While these concentrations were sufficient to mislocalize a detectable amount of K-Ras to the cytoplasm by Western blot at this time point, p-ERK levels remained high. This lack of activity could potentially be due to the increased expression of K-Ras that kept the level of membrane bound K-Ras consistent despite a portion now residing in the cytoplasm (Figures 4b,c and 5a) .
We reasoned that the potency of neo-substrate 6* could be enhanced by reduced competition with the natural substrate, farnesyl pyrophosphate. Statins, which decrease the cellular concentration of farnesyl pyrophosphate, may therefore increase the potency of 6* by allowing it to more effectively compete for the FTase active site. The cotreatment of cells with 1 μM Lovastatin plus 6* was sufficient to inhibit p-ERK signaling (Figure 5a ). The reverse combination experiment also showed that the addition of 10 μM 6* to a dose response of lovastatin also increased its ability to inhibit p-ERK (Figure 5b ). This increased activity was specific to the electrophilic compound 6* and not 8* or the peptide competitive FTase inhibitor ( Figure  5c ) and also resulted in an increase in the antiproliferative ability of 6* but not 8* in PSN-1 cells (Figure 5d ).
■ DISCUSSION
The term "undruggable target" serves as a placeholder until strategies are developed to overcome the unique challenges associated with the molecular recognition of proteins by small molecules that alter their biological output. While considerable effort has focused on how to drug structurally defined protein domains that lack obvious small molecule binding pockets, a less studied category of "undruggable" domains contains those with little or no stable tertiary structure. The most notorious example of an undruggable protein in oncology, oncogenic K-Ras, possesses two structural domains that typify each category: the structured G-domain responsible for engaging with effectors and initiating downstream signaling and the flexible C-terminal tail responsible for membrane localization. Recently, the G-domain has been successfully targeted by exploiting the unique chemical reactivity of the oncogenic G12C mutation. 27, 28 Here, we developed a chemical strategy to target the flexible C-terminal tail of K-Ras by taking advantage of its known biology to identify an interacting partner that offered a small molecule binding pocket that we could use to deliver our inhibitor in a targeted manner.
Previous generations of inhibitors targeting K-Ras localization focused on inhibiting the function of FTase itself, leaving the translated K-Ras CaaX motif available for prenylation by GGTase, which is sufficient for downstream processing and KRas localization. By directly targeting the cysteine side chain with a neo-substrate strategy, we were able to overcome this innate resistance mechanism and mislocalize K-Ras to the cytoplasm with a single agent. Other groups have previously tried to mislocalize K-Ras using unnatural farnesyl derivatives, but the resulting agents were either noncell permeable, or required high concentrations of an alcohol precursor that relied on subsequent cellular processing to form the necessary unnatural farnesyl pyrophosphate. 29−31 An alternative strategy to alter the localization of K-Ras by inhibiting the interaction between fully processed K-Ras and PDE-δ has also been described and has been shown to successfully alter oncogenic K-Ras signaling. 32, 33 While neosubstrate 6* was capable of inhibiting the proper cellular localization of K-Ras in cell lines containing oncogenic variants, it is likely that it would also affect other FTase substrates within the cell including wt K-Ras. This lack of mutant K-Ras vs wt K-Ras specificity may limit the ultimate therapeutic index of the neo-substrate strategy. One interesting feature of mutant KRas is the preferential use of splice variant −4B compared to wt K-Ras which commonly contains splice variant −4A. The two splice variants result in differential C-terminal tail sequences where farnesylation occurs. Splice variant −4B has been correlated with downregulation of noncanonical Wnt/Ca2+ signaling and more aggressive metastatic potential. 34 The K-Ras-4A sequence is closely related to the H-Ras C-terminal tail. 35 Since neo-substrate 6 distinguishes between K-Ras-4B and HRas, there may be some degree of selectivity between oncogenic K-Ras and wt K-Ras based on differential splice variants. We also do not anticipate any significant toxicity issues would be associated with 6* inhibition of farnesylation for the numerous other FTase substrates as previous generations of potent FTI's were well tolerated in the clinic and showed no serious adverse events associated their use. 10 The clinical failure of FTI's led to an abandonment of the therapeutic area. However, there is renewed interest in FTI's that although lacking in efficacy against K-Ras have been verified to be potent inhibitors of H-Ras and are currently being tested in clinical trials of patients harboring tumors with oncogenic H-Ras mutations. 36 These may soon lead to the long awaited breakthrough of Ras inhibitors, which our data suggests could eventually be expanded to a broader patient population harboring K-Ras mutations.
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